Danaher is expected to report Q2 2026 revenue of $5.91 billion and EPS of $1.84, with its current stock price of $284.12 trading below the consensus analyst target of $318.50. The central narrative for this report is the recovery of the Biotechnology segment and whether bioprocessing order trends show a definitive turn toward normalized growth.
Since streamlining its portfolio, Danaher's valuation has become highly sensitive to organic growth in life sciences and diagnostics. Investors will be scrutinizing management’s commentary on instrumentation demand in China and the potential for margin expansion as higher-margin bioprocessing volumes return to the mix.